Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Key Takeaways One shot a month of an experimental drug yielded promising results in a new clinical trialThe drug, called ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...